Celyad Oncology S.A. (CYAD)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Celyad Oncology S.A. (CYAD) trades at $0.47 with AI Score 57/100 (Grade B). Celyad Oncology SA is a clinical-stage biopharmaceutical company focused on developing CAR-T cell therapies for cancer treatment. Market cap: $14.24M, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for CYAD: CYAD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CYAD against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CYAD: the 4 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
Celyad Oncology S.A. (CYAD) Healthcare & Pipeline Overview
Celyad Oncology SA, a clinical-stage biopharmaceutical company based in Belgium, specializes in the discovery and development of CAR-T cell therapies for cancer, focusing on both allogeneic and autologous approaches to address unmet needs in hematologic malignancies and solid tumors, with a market capitalization of $0.01 billion.
What Is the Investment Thesis for CYAD?
Celyad Oncology presents a high-risk, high-reward investment opportunity within the CAR-T therapy space. The company's allogeneic CAR-T platform offers potential advantages in terms of scalability and accessibility compared to autologous approaches. Key value drivers include the successful progression of CYAD-101 in metastatic colorectal cancer and CYAD-211 in multiple myeloma through clinical trials. The company's market capitalization of $0.01 billion reflects the early stage of its pipeline and inherent risks associated with clinical-stage biopharmaceutical companies. Upcoming clinical trial results and potential partnerships will be critical catalysts. However, investors should be aware of potential risks, including clinical trial failures, regulatory hurdles, and the need for additional financing.
Based on FMP financials and quantitative analysis
CYAD Key Highlights
- Celyad Oncology focuses on CAR-T cell therapies, a rapidly evolving field in cancer treatment.
- The company's pipeline includes both allogeneic and autologous CAR-T candidates, diversifying its approach.
- CYAD-101 is in Phase 1b clinical trial for metastatic colorectal cancer, representing a key near-term catalyst.
- Celyad has a licensing agreement with Novartis for allogeneic CAR-T cell patents in the United States.
- The company's market capitalization is $0.01 billion, reflecting its early-stage development and associated risks.
Who Are CYAD's Competitors?
CYAD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AXLA Axcella Health Inc. | $4.58 | +0.00% | $12.50M | 44 |
| GLS Gelesis Holdings, Inc. | $0.16 | +0.00% | $11.63M | 61 |
| HURA TuHURA Biosciences, Inc. | $2.23 | +2.05% | $142.33M | 51 |
| IMNN Imunon, Inc. | $2.05 | +1.18% | $5.18M | 46 |
| SNDX Syndax Pharmaceuticals, Inc. | $18.25 | +1.90% | 2B | 79 |
| ANAB AnaptysBio, Inc. | $56.07 | +3.37% | 3B | 79 |
| ABCL AbCellera Biologics Inc. | $5.24 | -0.57% | 2B | 76 |
| CGEN Compugen Ltd. | $2.02 | -0.98% | $191.00M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CYAD's Key Strengths?
- Proprietary allogeneic CAR-T platform.
- Pipeline of CAR-T candidates in clinical development.
- Licensing agreement with Novartis.
- Experienced management team.
What Are CYAD's Weaknesses?
- Limited financial resources.
- Early-stage clinical development.
- High risk of clinical trial failure.
- Dependence on strategic partnerships.
What Could Drive CYAD Stock Higher?
- Clinical trial results for CYAD-101 in metastatic colorectal cancer.
- Clinical trial results for CYAD-211 in relapsed or refractory multiple myeloma.
- Clinical trial results for CYAD-02 in relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes.
- Strategic partnerships and licensing agreements with pharmaceutical companies.
- Advancement of allogeneic CAR-T platform.
What Are the Key Risks for CYAD?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from other CAR-T therapy developers.
- Need for additional financing.
- Dependence on strategic partnerships.
What Are the Growth Opportunities for CYAD?
- Expansion into Solid Tumors: Celyad's CYAD-203, a non-gene edited allogeneic CAR-T candidate targeting solid tumors, represents a significant growth opportunity. The solid tumor market is substantially larger than hematological malignancies, offering a broader patient population and potential for higher revenue. Preclinical data and early-stage clinical trials will be crucial in validating the efficacy and safety of CYAD-203. Success in this area could significantly increase Celyad's market value and attract partnerships with larger pharmaceutical companies. The timeline for this growth opportunity is estimated at 3-5 years, contingent on clinical trial progress.
- Advancement of Allogeneic CAR-T Platform: Celyad's allogeneic CAR-T platform offers a key advantage over autologous therapies by providing an 'off-the-shelf' product, reducing manufacturing time and costs. Further development and optimization of this platform could lead to broader adoption and increased market share. The company's research and development collaboration with Horizon Discovery Group plc for shRNA technology is crucial for enhancing the allogeneic platform. Successful development could position Celyad as a leader in allogeneic CAR-T therapy. The timeline for this is estimated at 2-4 years.
- Strategic Partnerships and Licensing Agreements: Celyad's licensing agreement with Novartis for allogeneic CAR-T cell patents in the United States demonstrates the value of its intellectual property. Pursuing additional strategic partnerships and licensing agreements with other pharmaceutical companies can provide non-dilutive funding and accelerate the development and commercialization of its CAR-T candidates. These partnerships can also provide access to new technologies and expertise. Identifying and securing these partnerships is a key growth driver. The timeline for securing additional partnerships is ongoing.
- Clinical Trial Success and Regulatory Approval: The successful completion of clinical trials and subsequent regulatory approval of CYAD-101, CYAD-211, or CYAD-02 would be a major catalyst for growth. Positive clinical data demonstrating efficacy and safety would significantly increase the company's valuation and attract investor interest. Regulatory approval would allow Celyad to commercialize its products and generate revenue. The timeline for regulatory approval depends on the progress of clinical trials and interactions with regulatory agencies. This is an ongoing opportunity.
- Expansion into New Therapeutic Areas: While Celyad's current pipeline focuses on specific hematologic malignancies and solid tumors, expanding into new therapeutic areas with high unmet medical needs could drive future growth. This could involve developing CAR-T therapies targeting different cancer types or exploring other cell-based therapies. Identifying and validating new therapeutic targets is crucial for this growth opportunity. The timeline for expansion into new therapeutic areas is estimated at 5+ years.
What Opportunities Does CYAD Have?
- Expansion into solid tumors.
- Further development of allogeneic CAR-T platform.
- Strategic partnerships and licensing agreements.
- Regulatory approval of CAR-T therapies.
What Threats Does CYAD Face?
- Competition from other CAR-T therapy developers.
- Clinical trial failures.
- Regulatory hurdles.
- Need for additional financing.
What Are CYAD's Competitive Advantages?
- Proprietary CAR-T cell therapy technologies.
- Allogeneic CAR-T platform offering scalability and accessibility advantages.
- Strategic partnerships and licensing agreements with leading pharmaceutical companies.
- Clinical data demonstrating the potential efficacy and safety of its CAR-T candidates.
What Does CYAD Do?
Founded in 2004 and headquartered in Mont-Saint-Guibert, Belgium, Celyad Oncology SA is a biopharmaceutical company dedicated to developing innovative cancer therapies. The company focuses on chimeric antigen receptor T-cell (CAR-T) therapies, exploring both autologous and allogeneic approaches. Their pipeline includes several CAR-T candidates in various stages of clinical development. Celyad's lead product candidates include CYAD-101, an allogeneic CAR-T candidate currently in Phase 1b clinical trial for metastatic colorectal cancer. CYAD-211, another allogeneic CAR-T candidate utilizing short hairpin RNA (shRNA) technology, is in Phase 1 clinical trial targeting relapsed or refractory multiple myeloma. CYAD-02, an autologous CAR-T candidate, is undergoing Phase 1 clinical trial for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company is also advancing CYAD-203, a preclinical, non-gene edited allogeneic CAR-T candidate designed to co-express interleukin-18 with natural killer group 2D ligands (NKG2D) for solid tumors. Celyad Oncology SA has strategic collaborations, including a licensing agreement with Novartis International AG for allogeneic CAR-T cell-related patents in the United States, and research and development agreements with Horizon Discovery Group plc for shRNA technology.
What Products and Services Does CYAD Offer?
- Develops chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment.
- Focuses on both allogeneic and autologous CAR-T approaches.
- Conducts clinical trials to evaluate the safety and efficacy of its CAR-T candidates.
- Utilizes shRNA technology to enhance its allogeneic CAR-T platform.
- Collaborates with pharmaceutical companies and research institutions.
- Aims to provide accessible and scalable CAR-T therapies for a broader patient population.
How Does CYAD Make Money?
- Develops and patents CAR-T cell therapy technologies.
- Conducts research and development to advance its pipeline of CAR-T candidates.
- Out-licenses its technologies and enters into strategic partnerships with pharmaceutical companies.
- Seeks regulatory approval for its CAR-T therapies to commercialize them.
What Industry Does CYAD Operate In?
Celyad Oncology operates in the competitive biotechnology industry, specifically within the CAR-T cell therapy market. This market is characterized by rapid innovation and significant unmet medical needs in cancer treatment. Key trends include the development of allogeneic CAR-T therapies to overcome limitations of autologous approaches, and the expansion of CAR-T technology to target solid tumors. Competitors include companies like ATON, AXLA, GLS, HURA, and IMNN, each pursuing different CAR-T strategies and target indications. The CAR-T therapy market is projected to experience substantial growth, driven by increasing cancer incidence and advancements in cell engineering technologies.
Who Are CYAD's Key Customers?
- Patients with cancer who are eligible for CAR-T cell therapy.
- Hospitals and cancer centers that administer CAR-T cell therapies.
- Pharmaceutical companies that partner with Celyad to develop and commercialize CAR-T therapies.
CYAD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Celyad's future prospects, indicating that leadership believes in the company's strategic direction.
- Positive sentiment from the community has been growing around Celyad's innovative therapies, particularly in the CAR-T cell therapy space.
- Recent announcements regarding clinical trial advancements have sparked interest, showcasing the company's commitment to research and development.
- Increased media coverage highlighting potential partnerships and collaborations has raised awareness and optimism among investors.
Bear Case
- Concerns over the competitive landscape in the oncology sector may dampen enthusiasm, as larger players continue to dominate.
- Recent market reactions to clinical trial setbacks have led to skepticism about Celyad's ability to deliver on its promises.
- Community discussions reveal a cautious outlook, with some investors expressing doubts about the scalability of Celyad's therapies.
- Insider selling activity in the past has raised red flags, leading to questions about the company's financial health and long-term strategy.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CYAD Latest News
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · Sep 29, 2022
-
Stocks That Hit 52-Week Lows On Friday
benzinga · Mar 4, 2022
CYAD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CYAD.
Price Targets
Wall Street price target analysis for CYAD.
CYAD MoonshotScore
What does this score mean?
The MoonshotScore rates CYAD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Georges Rawadi
CEO
Georges Rawadi serves as the CEO of Celyad Oncology SA, leading a team of 35 employees. His background includes extensive experience in the biopharmaceutical industry, with a focus on oncology and cell therapy development. He has held various leadership positions in both large pharmaceutical companies and smaller biotech firms. Rawadi's expertise spans from early-stage research to late-stage clinical development and commercialization. He holds advanced degrees in science and business administration.
Track Record: Under Georges Rawadi's leadership, Celyad Oncology SA has focused on advancing its pipeline of CAR-T cell therapy candidates. Key milestones include the progression of CYAD-101 into Phase 1b clinical trial for metastatic colorectal cancer and CYAD-211 into Phase 1 clinical trial for relapsed or refractory multiple myeloma. He has also overseen strategic collaborations and licensing agreements to support the company's research and development efforts.
Celyad Oncology S.A. ADR Information Sponsored
Celyad Oncology SA trades in the US as an American Depositary Receipt (ADR). An ADR is a certificate representing shares of a non-US company that are held by a US depositary bank. CYAD's ADR allows US investors to easily invest in the company without dealing with foreign exchanges or currencies. The ADR price generally reflects the value of the underlying shares in the home market, adjusted for the ADR ratio.
- Home Market Ticker: Euronext Brussels, Belgium
- ADR Level: 2
- ADR Ratio: 1:1
Celyad Oncology S.A. Healthcare Stock: Key Questions Answered
What does Celyad Oncology S.A. do?
Celyad Oncology SA is a clinical-stage biopharmaceutical company focused on developing innovative CAR-T cell therapies for the treatment of cancer. The company's pipeline includes both allogeneic and autologous CAR-T candidates targeting various hematologic malignancies and solid tumors. Celyad's allogeneic CAR-T platform offers the potential for 'off-the-shelf' therapies, reducing manufacturing time and costs compared to autologous approaches. Their lead product candidates are in Phase 1 clinical trials, evaluating safety and efficacy in patients with metastatic colorectal cancer, multiple myeloma, and acute myeloid leukemia.
What are the main risks for CYAD?
Celyad Oncology SA faces several key risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as the company's pipeline is still in early stages of development. Regulatory hurdles and potential delays in obtaining marketing approvals pose another challenge. Competition from other CAR-T therapy developers and larger pharmaceutical companies could limit Celyad's market share. The company's limited financial resources and dependence on strategic partnerships also create financial and operational risks. Investors should carefully consider these risks before investing in CYAD.
What are the key factors to evaluate for CYAD?
Celyad Oncology S.A. (CYAD) holds an AI score of 57/100 (moderate). Not financial advice.
How frequently does CYAD data refresh on this page?
CYAD prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CYAD's recent stock price performance?
Celyad Oncology S.A. (CYAD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary allogeneic CAR-T platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CYAD overvalued or undervalued right now?
Valuing Celyad Oncology S.A. (CYAD) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CYAD?
Before investing in Celyad Oncology S.A. (CYAD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CYAD to a portfolio?
Key strength of Celyad Oncology S.A. (CYAD): Proprietary allogeneic CAR-T platform. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for CYAD
- Information is based on publicly available sources and may be subject to change.
- This is not investment advice. Conduct thorough research before making any investment decisions.